ReviewACS pharmacology & translational science2026
Harnessing Anthocyanins to Mitigate Inflammation, Dysbiosis, and Aging in the Gastrointestinal Tract.
Review in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Berberine in Inflammatory Bowel Disease: Integrative Regulation of the Microbiota-Immune-Barrier Axis.International journal of molecular sciences · 2026Review
- Functional foods and their potential impact on women's health in Chile.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota are a dynamic ecosystem that is crucial for immune regulation and maintenance of intestinal barrier integrity. Dysbiosis within this community contributes to the chronic inflammation characteristic of inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, for which no definitive cure currently exists. This comprehensive review examines recent preclinical and clinical studies on how anthocyanin-polyphenolic pigments, such as cyanidins and malvidins, modulate gut microbial communities, reduce intestinal inflammation, and counteract age-related declines in immune homeostasis. We analyzed the literature on anthocyanin-microbiota interactions in IBD pathogenesis, focusing on cytokine profiles, barrier function assays, lipopolysaccharide synthesis, oxidative stress markers, and short-chain fatty acid production. Additionally, we explored the relationship among cellular senescence, the senescence-associated secretory phenotype (SASP), and microbiome shifts during intestinal aging. Evidence indicates that anthocyanins consistently suppress key pro-inflammatory cytokines, such as interleukin-1β, interleukin-6, TNF-α, and interferon-γ, while preserving mucosal architecture and reducing lipopolysaccharide load and mitochondrial oxidative phosphorylation. These compounds help to restore microbial balance, promote short-chain fatty acid synthesis, and enrich bacterial taxa associated with barrier integrity. In aging models, anthocyanins attenuate oxidative stress, stabilize redox homeostasis, inhibit senescence signaling and SASP secretion, and partially restore anti-inflammatory interleukin-10 levels. In conclusion, anthocyanins are promising dietary therapeutics for IBD management and for mitigating intestinal aging. Future research should transition from murine models to human clinical trials by integrating senolytic strategies, targeted microbiome modulation, and pharmacological dissection of the senescence-microbiome axis to foster disease prevention and promote healthy aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.